LT2968434T - C1-inh kompozicijos, skirtos panaudoti paveldimos angiodemos prevencijai ir gydymui - Google Patents

C1-inh kompozicijos, skirtos panaudoti paveldimos angiodemos prevencijai ir gydymui

Info

Publication number
LT2968434T
LT2968434T LTEP14762343.3T LT14762343T LT2968434T LT 2968434 T LT2968434 T LT 2968434T LT 14762343 T LT14762343 T LT 14762343T LT 2968434 T LT2968434 T LT 2968434T
Authority
LT
Lithuania
Prior art keywords
hae
prevention
treatment
hereditary angioedema
inh
Prior art date
Application number
LTEP14762343.3T
Other languages
English (en)
Lithuanian (lt)
Inventor
Cynthia GALLAGHER
Stephen Ruddy
Mark Cornell MANNING
Original Assignee
Shire Viropharma Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2968434(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Incorporated filed Critical Shire Viropharma Incorporated
Publication of LT2968434T publication Critical patent/LT2968434T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
LTEP14762343.3T 2013-03-15 2014-03-17 C1-inh kompozicijos, skirtos panaudoti paveldimos angiodemos prevencijai ir gydymui LT2968434T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
PCT/US2014/030309 WO2014145519A2 (en) 2013-03-15 2014-03-17 C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Publications (1)

Publication Number Publication Date
LT2968434T true LT2968434T (lt) 2017-09-25

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17177676.8T LT3290046T (lt) 2013-03-15 2014-03-17 C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai
LTEP14762343.3T LT2968434T (lt) 2013-03-15 2014-03-17 C1-inh kompozicijos, skirtos panaudoti paveldimos angiodemos prevencijai ir gydymui

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP17177676.8T LT3290046T (lt) 2013-03-15 2014-03-17 C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai

Country Status (30)

Country Link
US (9) US9616111B2 (OSRAM)
EP (3) EP2968434B1 (OSRAM)
JP (9) JP6184581B2 (OSRAM)
KR (4) KR102430453B1 (OSRAM)
CN (2) CN105517559A (OSRAM)
AU (3) AU2014232912A1 (OSRAM)
BR (1) BR112015023207A8 (OSRAM)
CA (2) CA2904543C (OSRAM)
CY (2) CY1119419T1 (OSRAM)
DE (1) DE202014011208U1 (OSRAM)
DK (2) DK2968434T3 (OSRAM)
EA (1) EA201591278A1 (OSRAM)
ES (2) ES2713004T3 (OSRAM)
GB (1) GB2530921B (OSRAM)
HK (1) HK1250912B (OSRAM)
HR (2) HRP20171269T1 (OSRAM)
HU (2) HUE036224T2 (OSRAM)
IL (2) IL241549B (OSRAM)
LT (2) LT3290046T (OSRAM)
ME (2) ME02865B (OSRAM)
MX (3) MX373965B (OSRAM)
PL (2) PL3290046T3 (OSRAM)
PT (2) PT2968434T (OSRAM)
RS (2) RS58351B1 (OSRAM)
SG (2) SG10201707598QA (OSRAM)
SI (2) SI3290046T1 (OSRAM)
SM (2) SMT201700415T1 (OSRAM)
TR (1) TR201900319T4 (OSRAM)
WO (1) WO2014145519A2 (OSRAM)
ZA (3) ZA201507604B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202014011208U1 (de) 2013-03-15 2018-08-23 Shire Viropharma Incorporated C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind
PL3071219T3 (pl) * 2013-11-22 2019-04-30 Shire Viropharma Inc Sposoby leczenia zależnego od przeciwciała odrzucenia przeszczepu narządu u pacjentów za pomocą inhibitora esterazy c1
JP6516855B2 (ja) * 2015-02-20 2019-05-22 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤の医薬製剤
CN113999875A (zh) * 2015-05-28 2022-02-01 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
MA43270A (fr) * 2015-11-19 2021-06-02 Takeda Pharmaceuticals Co Inhibiteur de la c1 estérase humaine recombinante et ses utilisations
CN109562149A (zh) * 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
JP2019534240A (ja) * 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
AU2019226355A1 (en) 2018-02-28 2020-09-17 Pharming Intellectual Property B.V. Treatment and prevention of pre-eclampsia
WO2019245038A1 (ja) 2018-06-22 2019-12-26 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法
EP3845652A4 (en) 2018-06-22 2022-04-13 JUNTEN BIO Co., Ltd. ANTIBODIES FOR INDUCING IMMUNTOLERANCE, INDUCED LYMPHOCYTE AND THERAPEUTIC METHOD WITH CELL THERAPY AGENT USING INDUCED LYMPHOCYTE
AU2019288684A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Composition for eliciting infectious immunological tolerance
US20230041642A1 (en) * 2019-12-16 2023-02-09 Nipro Corporation Aggregation Inhibitory Agent and Medical Composition and Medical Device Including Same
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
US20240342258A1 (en) 2021-07-09 2024-10-17 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
JP4077030B2 (ja) * 1993-09-01 2008-04-16 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 急性心筋梗塞中の心筋傷害の低減方法
WO1997022347A1 (en) 1995-12-18 1997-06-26 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
EP1252184B1 (en) 2000-01-31 2008-01-02 Pharming Intellectual Property B.V. Human c1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003300781A1 (en) 2002-09-25 2004-05-04 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
ES2830499T3 (es) 2003-05-16 2021-06-03 Pharming Intellectual Property B V Inhibidor de C1 con una semivida corta para un tratamiento transitorio
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
WO2006131874A2 (en) 2005-06-06 2006-12-14 Univ Cape Town Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
PT1965831E (pt) * 2005-12-21 2011-10-19 Pharming Intellectual Pty Bv Uso de inibidor c1 para a prevenção da lesão isquémia-reperfusão
JP5394748B2 (ja) 2005-12-21 2014-01-22 ファーミング インテレクチュアル プロパティ ビー．ブイ． 虚血再灌流障害を予防するためのｃ１インヒビターの使用
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
CA2678001C (en) 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RU2473360C2 (ru) 2007-11-30 2013-01-27 Эббот Лэборетриз Белковые композиции и способы их получения
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
EP2542569B1 (en) 2010-03-05 2020-09-16 Omeros Corporation Chimeric inhibitor molecules of complement activation
US20130085111A1 (en) * 2010-03-18 2013-04-04 Thrombolytic Science, Llc Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
EP2758076B1 (en) 2011-09-24 2018-12-12 CSL Behring GmbH Combination therapy using immunoglobulin and c1-inhibitor
EP2793935B1 (en) 2011-12-22 2016-05-25 CSL Behring GmbH Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
CA2867593A1 (en) 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c-1 inhibitors
CA2902841A1 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
DE202014011208U1 (de) 2013-03-15 2018-08-23 Shire Viropharma Incorporated C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム

Also Published As

Publication number Publication date
ZA201706929B (en) 2019-05-29
KR102430453B1 (ko) 2022-08-05
MX2020004724A (es) 2022-01-18
KR20220070049A (ko) 2022-05-27
GB201519921D0 (en) 2015-12-23
JP6877470B2 (ja) 2021-05-26
SG11201507616VA (en) 2015-10-29
IL276153A (en) 2020-09-30
AU2020203183A1 (en) 2020-06-04
SG10201707598QA (en) 2017-10-30
MX2021011946A (es) 2021-11-17
US20180085441A1 (en) 2018-03-29
CY1121653T1 (el) 2020-07-31
GB2530921B (en) 2017-09-20
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
HUE041837T2 (hu) 2019-05-28
EP3508213A1 (en) 2019-07-10
JP2018119001A (ja) 2018-08-02
BR112015023207A2 (pt) 2017-11-21
IL276153B (en) 2022-06-01
MX389449B (es) 2025-03-20
MX373965B (es) 2020-07-13
CA2904543C (en) 2019-10-08
JP6877471B2 (ja) 2021-05-26
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
US20160015795A1 (en) 2016-01-21
PL2968434T3 (pl) 2018-01-31
CA2904543A1 (en) 2014-09-18
KR102579789B1 (ko) 2023-09-15
IL241549B (en) 2020-08-31
NZ751555A (en) 2021-07-30
DK3290046T3 (en) 2019-03-18
US20180110844A1 (en) 2018-04-26
DK2968434T3 (en) 2017-09-11
ZA201507604B (en) 2018-05-30
JP2018119002A (ja) 2018-08-02
JP2021088599A (ja) 2021-06-10
AU2014232912A1 (en) 2015-09-03
ES2639833T3 (es) 2017-10-30
JP2019073545A (ja) 2019-05-16
KR20210129267A (ko) 2021-10-27
JP6422520B2 (ja) 2018-11-14
EP2968434A2 (en) 2016-01-20
BR112015023207A8 (pt) 2018-01-23
ME02865B (me) 2018-04-20
SMT201700415T1 (it) 2017-11-15
EP2968434A4 (en) 2016-03-02
HRP20171269T1 (hr) 2017-11-03
JP2019073544A (ja) 2019-05-16
CA3054718A1 (en) 2014-09-18
JP6473535B2 (ja) 2019-02-20
EP3290046B1 (en) 2019-01-02
EA201591278A1 (ru) 2016-03-31
US9616111B2 (en) 2017-04-11
JP6877472B2 (ja) 2021-05-26
US20200261556A1 (en) 2020-08-20
US11534482B2 (en) 2022-12-27
AU2018229558B2 (en) 2020-03-05
AU2020203183B2 (en) 2022-06-02
HK1220403A1 (en) 2017-05-05
LT3290046T (lt) 2019-03-12
JP2016516073A (ja) 2016-06-02
HRP20190270T1 (hr) 2019-04-05
SMT201900141T1 (it) 2019-05-10
US10105423B2 (en) 2018-10-23
ZA201806793B (en) 2020-01-29
JP6473536B2 (ja) 2019-02-20
HK1250912B (en) 2020-01-10
CY1119419T1 (el) 2018-03-07
ME03326B (me) 2019-10-20
JP2018119000A (ja) 2018-08-02
WO2014145519A2 (en) 2014-09-18
CN105517559A (zh) 2016-04-20
MX2015011281A (es) 2016-03-03
US20170224788A1 (en) 2017-08-10
GB2530921A (en) 2016-04-06
PL3290046T3 (pl) 2019-05-31
US20190160157A1 (en) 2019-05-30
JP6473534B2 (ja) 2019-02-20
US20190160158A1 (en) 2019-05-30
HUE036224T2 (hu) 2018-06-28
TR201900319T4 (tr) 2019-02-21
SI3290046T1 (sl) 2019-04-30
PT2968434T (pt) 2017-09-18
US11364288B2 (en) 2022-06-21
CN111529708A (zh) 2020-08-14
PT3290046T (pt) 2019-02-18
DE202014011208U1 (de) 2018-08-23
JP2019073546A (ja) 2019-05-16
JP6184581B2 (ja) 2017-08-23
ES2713004T3 (es) 2019-05-17
SI2968434T1 (sl) 2017-11-30
WO2014145519A3 (en) 2014-12-31
RS58351B1 (sr) 2019-03-29
US10080788B2 (en) 2018-09-25
KR20210021146A (ko) 2021-02-24
JP2017105847A (ja) 2017-06-15
EP3290046A1 (en) 2018-03-07
AU2018229558A1 (en) 2018-10-04
KR20150135242A (ko) 2015-12-02
EP2968434B1 (en) 2017-06-28
US20180153972A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
PL2968434T3 (pl) Kompozycje c1-inh do stosowania w zapobieganiu i leczeniu dziedzicznego obrzęku naczynioruchowego (hae)
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
IL246864B (en) Plasma kallikrein-binding proteins and their uses in the treatment of hereditary angioedema
PT2945642T (pt) Proteína do fator 1 para utilização no tratamento ou prevenção de doenças
EP3052510A4 (en) Methods and compositions for treating and/or preventing mucositis
EP3038474A4 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
EP2905337A4 (en) AMPHIREGULIN SPECIFIC DOUBLE HELIX OLIGO RNA, DOUBLE HELIX OLIGO RNA STRUCTURE WITH THE DOUBLE HELIX OLIGO RNA AND COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASES THEREWITH
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
IL235035A0 (en) A preparation to prevent an effect on blood vessels in the treatment of blood loss and anemia
SMT202100490T1 (it) Composizione comprendente geraniolo e zenzero secco per l'uso nel trattamento della sindrome del colon irritabile
GB201513543D0 (en) Compositions for use in the treatment of diabetes
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
PT2862576T (pt) Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
IL247616B (en) Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit
AU2013904048A0 (en) Compositions and methods for the prevention and/or treatment of neurogenic inflammation and/or infla
TH1401007825A (th) องค์ประกอบที่มีน้ำชาสำหรับการป้องกันการเปลี่ยนตามวัยของผิวหนัง